A controlled clinical study employing a double-blind, double-dummy technique was carried out on 84 patients with purulent exacerbations of chronic bronchitis. Ofloxacin (200 mg x 2 daily) and pivampicillin (700 mg x 3 daily), were compared for efficacy, safety, and adverse reactions. Both regimens had high bacteriological elimination rates (94.1, 97.2%) and clinical cure rates (97.4, 97.6%). However, there were fewer adverse reactions and a greater patient acceptance in the ofloxacin treated group.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/02/2016 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/3182456